Aug. 5 at 7:35 PM
$GOSS CEO's last company Receptos was sold to Celgene
$7.2 billyballoons.
I asked Chad Gepeto to tell me at which stage in its drug development did Celgene acquire Receptos.
"Celgene announced its agreement to acquire Receptos on July 14, 2015, in a deal worth approximately US
$7.2 billion . Receptos’ primary asset at the time was ozanimod, a small‑molecule modulator of sphingosine‑1‑phosphate (S1P) receptors targeting immune‑inflammatory conditions, which was already in late‑stage clinical development (Phase III) for both ulcerative colitis and relapsing multiple sclerosis"
It was in late stage Phase 3.
Isn't this where we are today?
